{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T09:53:45Z","timestamp":1769594025466,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gilead Sciences Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-12306-7","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T07:34:42Z","timestamp":1737963282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world assessment to estimate multiple attributes related to treatment cost driver for mantle cell lymphoma in Japan by econometric modeling"],"prefix":"10.1186","volume":"25","author":[{"given":"Saaya","family":"Tsutsu\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Asou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anila","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Idehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilinuer","family":"Ainiwaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"5","key":"12306_CR1","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1080\/03007995.2020.1742101","volume":"36","author":"N Monga","year":"2020","unstructured":"Monga N, Garside J, Quigley J, et al. Systematic literature review of the global burden of illness of mantle cell lymphoma. Curr Med Res Opin. 2020;36(5):843\u201352. https:\/\/doi.org\/10.1080\/03007995.2020.1742101. Epub 2020\/03\/13. PubMed PMID: 32162977.","journal-title":"Curr Med Res Opin."},{"key":"12306_CR2","unstructured":"Lynch DT, Koya S, Acharya U, et al. Mantle Cell Lymphoma. StatPearls. Treasure Island (FL) ineligible companies. 2023."},{"issue":"68","key":"12306_CR3","doi-asserted-by":"publisher","first-page":"112516","DOI":"10.18632\/oncotarget.22367","volume":"8","author":"S Fu","year":"2017","unstructured":"Fu S, Wang M, Lairson DR, et al. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. Oncotarget. 2017;8(68):112516\u201329. https:\/\/doi.org\/10.18632\/oncotarget.22367. Epub 2018\/01\/20. PubMed PMID: 29348844; PubMed Central PMCID: PMCPMC5762529.","journal-title":"Oncotarget."},{"issue":"10","key":"12306_CR4","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.22034\/apjcp.2016.17.10.4583","volume":"17","author":"ChK Das","year":"2016","unstructured":"Das ChK, Gogia A, Kumar L, et al. Mantle cell lymphoma: a North Indian tertiary care centre experience. Asian Pac J Cancer Prev. 2016;17(10):4583\u20136. https:\/\/doi.org\/10.22034\/apjcp.2016.17.10.4583. Epub 2016\/11\/29. PubMed PMID: 27892666; PubMed Central PMCID: PMCPMC5454601.","journal-title":"Asian Pac J Cancer Prev."},{"key":"12306_CR5","first-page":"12","volume":"21","author":"N Howlader","year":"2013","unstructured":"Howlader N, Noone A-M, Krapcho M, et al. SEER cancer statistics review, 1975\u20132010. Bethesda, MD: National Cancer Institute. 2013;21:12.","journal-title":"Bethesda, MD: National Cancer Institute"},{"issue":"4","key":"12306_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12185-018-2430-6","volume":"107","author":"H Miyoshi","year":"2018","unstructured":"Miyoshi H, Ohshima K. Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia\/lymphoma in Japan. Int J Hematol. 2018;107(4):420\u20137. https:\/\/doi.org\/10.1007\/s12185-018-2430-6. Epub 2018\/03\/05. PubMed PMID: 29502313.","journal-title":"Int J Hematol."},{"issue":"suppl_4","key":"12306_CR7","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv62\u201371. https:\/\/doi.org\/10.1093\/annonc\/mdx223. Epub 2017\/09\/09. PubMed PMID: 28881919.","journal-title":"Ann Oncol."},{"issue":"4","key":"12306_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","volume":"157","author":"JI Sive","year":"2012","unstructured":"Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial. Br J Haematol. 2012;157(4):463\u201371. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09095.x. Epub 2012\/03\/14. PubMed PMID: 22409379; PubMed Central PMCID: PMCPMC4188419.","journal-title":"Br J Haematol."},{"issue":"11","key":"12306_CR9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1634\/theoncologist.2017-0470","volume":"23","author":"H Ye","year":"2018","unstructured":"Ye H, Desai A, Zeng D, et al. Frontline treatment for older patients with mantle cell lymphoma. Oncologist. 2018;23(11):1337\u201348. https:\/\/doi.org\/10.1634\/theoncologist.2017-0470. Epub 2018\/06\/14. PubMed PMID: 29895632; PubMed Central PMCID: PMCPMC6291324.","journal-title":"Oncologist."},{"key":"12306_CR10","doi-asserted-by":"publisher","first-page":"588314","DOI":"10.3389\/fonc.2020.588314","volume":"10","author":"H Wu","year":"2020","unstructured":"Wu H, Wang J, Zhang X, et al. Survival trends in patients under age 65 years with mantle cell lymphoma, 1995\u20132016: a SEER-based analysis. Front Oncol. 2020;10:588314. https:\/\/doi.org\/10.3389\/fonc.2020.588314. Epub 2020\/11\/17. PubMed PMID: 33194744; PubMed Central PMCID: PMCPMC7606943.","journal-title":"Front Oncol."},{"key":"12306_CR11","unstructured":"Japanese Society of Hematology (JSH). [JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-4. Mantle cell lymphoma (MCL)] (in Japanese). http:\/\/www.jshem.or.jp\/gui-hemali\/2_4.html."},{"key":"12306_CR12","doi-asserted-by":"publisher","unstructured":"Burkart M, Karmali R. Relapsed\/refractory mantle cell lymphoma: beyond BTK inhibitors. J Pers Med. 2022;12(3). https:\/\/doi.org\/10.3390\/jpm12030376. Epub 2022\/03\/26. PubMed PMID: 35330376; PubMed Central PMCID: PMCPMC8954159.","DOI":"10.3390\/jpm12030376"},{"issue":"11","key":"12306_CR13","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s00277-021-04650-5","volume":"100","author":"R Wullenkord","year":"2021","unstructured":"Wullenkord R, Berning P, Niemann AL, et al. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis. Ann Hematol. 2021;100(11):2733\u201344. https:\/\/doi.org\/10.1007\/s00277-021-04650-5. Epub 2021\/09\/04. PubMed PMID: 34477953; PubMed Central PMCID: PMCPMC8510902.","journal-title":"Ann Hematol"},{"issue":"9","key":"12306_CR14","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1111\/cas.13719","volume":"109","author":"M Ogura","year":"2018","unstructured":"Ogura M, Yamamoto K, Morishima Y, et al. R-High-CHOP\/CHASER\/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. Cancer Sci. 2018;109(9):2830\u201340. https:\/\/doi.org\/10.1111\/cas.13719. Epub 2018\/06\/30. PubMed PMID: 29957865; PubMed Central PMCID: PMCPMC6125440.","journal-title":"Cancer Sci."},{"issue":"2","key":"12306_CR15","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.3747\/co.26.4345","volume":"26","author":"C Owen","year":"2019","unstructured":"Owen C, Berinstein NL, Christofides A, et al. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26(2):e233\u201340. https:\/\/doi.org\/10.3747\/co.26.4345. Epub 2019\/05\/03. PubMed PMID: 31043832; PubMed Central PMCID: PMCPMC6476444.","journal-title":"Curr Oncol."},{"issue":"14","key":"12306_CR16","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347. Epub 2020\/04\/04. PubMed PMID: 32242358; PubMed Central PMCID: PMCPMC7731441.","journal-title":"N Engl J Med."},{"issue":"3","key":"12306_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol. 2023;41(3):555\u201367. https:\/\/doi.org\/10.1200\/JCO.21.02370. Epub 2022\/06\/07. PubMed PMID: 35658525.","journal-title":"J Clin Oncol."},{"key":"12306_CR18","unstructured":"Databases available for pharmacoepidemiology researches in Japan: Japanese Society for Pharmacoepidemiology; 2022. Available from: https:\/\/www.jspe.jp\/mt-static\/FileUpload\/files\/JSPE_DB_TF_E.pdf."},{"key":"12306_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/978-1-61779-555-8_27","volume":"850","author":"CM Stein","year":"2012","unstructured":"Stein CM, Morris NJ, Nock NL. Structural equation modeling. Methods Mol Biol. 2012;850:495\u2013512. https:\/\/doi.org\/10.1007\/978-1-61779-555-8_27. Epub 2012\/02\/07. PubMed PMID: 22307716.","journal-title":"Methods Mol Biol."},{"key":"12306_CR20","doi-asserted-by":"publisher","first-page":"614770","DOI":"10.3389\/fpsyg.2020.614770","volume":"11","author":"X Sang","year":"2020","unstructured":"Sang X, Menhas R, Saqib ZA, et al. The psychological impacts of COVID-19 home confinement and physical activity: a structural equation model analysis. Front Psychol. 2020;11:614770. https:\/\/doi.org\/10.3389\/fpsyg.2020.614770. Epub 2021\/02\/02. PubMed PMID: 33519638; PubMed Central PMCID: PMCPMC7843378.","journal-title":"Front Psychol."},{"issue":"5","key":"12306_CR21","doi-asserted-by":"publisher","first-page":"e0269169","DOI":"10.1371\/journal.pone.0269169","volume":"17","author":"S Tsutsu\u00e9","year":"2022","unstructured":"Tsutsu\u00e9 S, Makita S, Yi J, et al. Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: a structural equation model (SEM) analysis. PLoS ONE. 2022;17(5):e0269169. https:\/\/doi.org\/10.1371\/journal.pone.0269169.","journal-title":"PLoS ONE"},{"key":"12306_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v048.i02","volume":"48","author":"Y Rosseel","year":"2012","unstructured":"Rosseel Y. lavaan: an R package for structural equation modeling. J Stat Softw. 2012;48:1\u201336.","journal-title":"J Stat Softw"},{"key":"12306_CR23","doi-asserted-by":"publisher","unstructured":"Hu L-t, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equ Model. 1999;6(1):1\u201355. https:\/\/doi.org\/10.1080\/10705519909540118.","DOI":"10.1080\/10705519909540118"},{"issue":"4","key":"12306_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s12185-016-2146-4","volume":"105","author":"M Ogura","year":"2017","unstructured":"Ogura M, Ishizawa K, Maruyama D, et al. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan. Int J Hematol. 2017;105(4):470\u20137. https:\/\/doi.org\/10.1007\/s12185-016-2146-4. Epub 2016\/12\/03. PubMed PMID: 27900638.","journal-title":"Int J Hematol."},{"issue":"9","key":"12306_CR25","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00277-019-03750-7","volume":"98","author":"R Sakai","year":"2019","unstructured":"Sakai R, Ohmachi K, Sano F, et al. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study. Ann Hematol. 2019;98(9):2131\u20138. https:\/\/doi.org\/10.1007\/s00277-019-03750-7. Epub 2019\/07\/10. PubMed PMID: 31286196.","journal-title":"Ann Hematol."},{"issue":"3","key":"12306_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3960\/jslrt.20056","volume":"61","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Suzumiya J, Takizawa J, et al. Real world treatment practices for mantle cell lymphoma in Japan: an observational database research study (CLIMBER-DBR). J Clin Exp Hematop. 2021;61(3):135\u201344. https:\/\/doi.org\/10.3960\/jslrt.20056. Epub 2021\/06\/08. PubMed PMID: 34092722; PubMed Central PMCID: PMCPMC8519241.","journal-title":"J Clin Exp Hematop."},{"issue":"4","key":"12306_CR27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/10428194.2018.1509320","volume":"60","author":"RK Goyal","year":"2019","unstructured":"Goyal RK, Nagar SP, Kabadi SM, et al. Adverse events, resource use, and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the United States. Leuk Lymphoma. 2019;60(4):955\u201363. https:\/\/doi.org\/10.1080\/10428194.2018.1509320. Epub 2018\/10\/03. PubMed PMID: 30277099; PubMed Central PMCID: PMCPMC7564890.","journal-title":"Leuk Lymphoma."},{"key":"12306_CR28","doi-asserted-by":"publisher","unstructured":"Kabadi SM, Near A, Wada K, et al. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. Cancer Med. 2019;8(17):7174\u201385. Epub 2019\/10\/09. https:\/\/doi.org\/10.1002\/cam4.2559. PubMed PMID: 31595715; PubMed Central PMCID: PMCPMC6885896.","DOI":"10.1002\/cam4.2559"},{"issue":"2","key":"12306_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bjh.15170","volume":"181","author":"A Smith","year":"2018","unstructured":"Smith A, Roman E, Appleton S, et al. Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK\u2019s Haematological Malignancy Research Network (HMRN). Br J Haematol. 2018;181(2):215\u201328. https:\/\/doi.org\/10.1111\/bjh.15170. Epub 2018\/03\/14. PubMed PMID: 29532919; PubMed Central PMCID: PMCPMC5947165.","journal-title":"Br J Haematol."},{"issue":"4","key":"12306_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/fon-2020-0832","volume":"17","author":"S Tsutsue","year":"2021","unstructured":"Tsutsue S, Tobinai K, Yi J, et al. Comparative effectiveness study of chemotherapy in follicular lymphoma patients in the rituximab era: a Japanese claims database study. Future Oncol. 2021;17(4):455\u201369. https:\/\/doi.org\/10.2217\/fon-2020-0832. Epub 2020\/10\/07. PubMed PMID: 33021099.","journal-title":"Future Oncol."},{"issue":"5","key":"12306_CR31","doi-asserted-by":"publisher","first-page":"e0269169","DOI":"10.1371\/journal.pone.0269169","volume":"17","author":"S Tsutsue","year":"2022","unstructured":"Tsutsue S, Makita S, Yi J, et al. Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: a structural equation model (SEM) analysis. PLoS One. 2022;17(5):e0269169. https:\/\/doi.org\/10.1371\/journal.pone.0269169. PubMed PMID: 35622820; PubMed Central PMCID: PMCPMC9140275.","journal-title":"PLoS One."},{"issue":"1","key":"12306_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/1078-0432.CCR-23-1272","volume":"30","author":"D Telaraja","year":"2024","unstructured":"Telaraja D, Kasamon YL, Collazo JS, et al. FDA approval summary: pirtobrutinib for relapsed or refractory mantle cell lymphoma. Clin Cancer Res. 2024;30(1):17\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1272. Epub 2023\/08\/25. PubMed PMID: 37624619; PubMed Central PMCID: PMCPMC10841293.","journal-title":"Clin Cancer Res."},{"key":"12306_CR33","unstructured":"FDA. FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-mantle-cell-lymphoma. 2024."},{"key":"12306_CR34","first-page":"3442","volume":"130","author":"S Karve","year":"2017","unstructured":"Karve S, Nagar S, Goyal R, et al. Adverse events, resource use, and economic burden in patients with mantle cell lymphoma in the United States. Blood. 2017;130:3442.","journal-title":"Blood"},{"key":"12306_CR35","unstructured":"Ministry of Education, Culture, Sports, Science and Technology (MEXT), Ministry of Health, labor and Welfare (MHLW) & Ministry of Economy, Trade and Industry (METI). [Ethical guidelines for life science and medical research involving human subjects] (in Japanese). https:\/\/www.mhlw.go.jp\/content\/001077424.pdf."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12306-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-12306-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-12306-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T07:34:48Z","timestamp":1737963288000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-12306-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12306"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-12306-7","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval and informed consent were not applicable for this study, in accordance with the Ethical Guidelines for Epidemiological Research issued by the Japanese Ministry of Health, Labor and Welfare []. A review by an institutional review board (IRB) or independent ethics committee (IEC) was not required for the secondary analysis of existing data. Personal identifiers of patients were removed from all data sources.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.T., H.A., and A.M. are current employees of Gilead Sciences Japan. S.M. has received honoraria from AbbVie, Celgene\/BMS, Chugai, CSL Behring, Eisai, Novartis, SymBio, and Takeda outside of this work. Y. K., K.I., SW.K., D.A. are current employees of IQVIA Solutions Japan. There are no patents, products in development, or marketed products to declare for the target regimens of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}